Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J rivaroxaban (correction)

Executive Summary

Johnson & Johnson is developing the anticoagulant as an oral product only, not in multiple formulations. In a recent analyst update, the company suggested the product would offer an advantage in that the oral agent can be used both in the hospital and then later in the home (1"The Pink Sheet" June 11, 2007, p. 19)...

You may also be interested in...

J&J Growth Plan Calls For Four Virology Filings In As Many Years

Johnson & Johnson's next generation non-nucleoside reverse transcriptase inhibitor TMC 125 is on deck to be the first of the firm's four virology NDAs over the next four years, Group Chairman Julie McHugh said during an analyst update outlining the company's growth strategy in New Brunswick, N.J. June 7

OTC Drug Oversight By US FDA Split Among Two Divisions In Reorganization

CDER Office of New Drugs changes its organization including establishing Office of Nonprescription Drugs and splitting the office into Division of Nonprescription Drug Products I and DNDP II. A Division of Regulatory Operations for Nonprescription Drugs will be comprised of regulatory staff from the ONPD divisions and will report to OND’s regulatory office. Non-clinical ONPD staff will report to the office director.

Verrica Ready To Target Pediatric Dermatologists With First Molluscum Therapy

Anticipating a July approval of its cantharidin formulation, Verrica says it is poised to implement a buy-and-bill model for a clinician-administered product with an addressable market of 6 million.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts